inebilizumab – Medxy AI

Inebilizumab Significantly Reduces Exacerbations and Need for Rescue Therapy in Generalized Myasthenia Gravis: Insights from the Phase 3 MINT Trial

By MedXY 08/14/2026

The MINT trial demonstrates that inebilizumab markedly lowers exacerbation rates and rescue therapy use in AChR+ and MuSK+ generalized myasthenia gravis patients undergoing corticosteroid tapering.

Neurology news

FDA Approves Inebilizumab (Uplizna) for Antibody-Positive Generalized Myasthenia Gravis: Interpreting the MINT Trial and Clinical Implications

By MedXY 12/15/2025

The FDA has approved inebilizumab-cdon (Uplizna) for adults with AChR- or MuSK-antibody positive generalized myasthenia gravis based on the phase 3 MINT trial showing a 1.9-point MG‑ADL improvement at 26 weeks versus placebo and sustained benefit in AChR+ patients through 52 weeks.

Clinical Updates Diabetes & Endocrinology news Specialties

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY 08/01/2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.